Skip to content
Peptigraph home

CJC-1295 + Ipamorelin vs Sermorelin: What the Research Shows

CJC-1295 + Ipamorelin and Sermorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[15]Growth hormonePre-mixed blendGHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[16]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider CJC-1295 + Ipamorelin if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[16]

What they have in common

  • Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[17]
  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[1]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldCJC-1295 + IpamorelinSermorelin
ClassGHRH + GHRP blendGHRH analog
Also calledCJC/Ipa—
FDA statusNot FDA approved · research blendCompounded by prescription
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658No published half-life foundPubMed search, 11 Oct 2026
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients6 human (1 randomized or controlled) of 9 summarised
Typical study doses
Vial sizes sold10 mg2 mg, 5 mg, 9 mg, 15 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

CJC-1295 + Ipamorelin and Sermorelin together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 4 results, 2 Oct 2026).

Open the stack page

Blend components and sermorelin

Sermorelin is described as a 29 amino acid analogue of human GHRH and the shortest synthetic peptide with full biological activity of GHRH.[19]

Ipamorelin's randomized trial title describes it as a ghrelin mimetic.[4]

The nearest human data for a blend-like regimen is a retrospective chart review of men on testosterone who were prescribed GHRP-6, GHRP-2 and sermorelin together; 14 met the inclusion criteria and their mean IGF-1 rose from 159.5 to 239.0 ng/mL.[9]

The authors of that chart review state that GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing.[9]

In older men, twice-daily subcutaneous GHRH injections evoked dose-related increases in GH, with significant differences only at the high dose.[8]

Product status and what is missing

Sermorelin's record shows it as a former product: the review notes the only US maker of recombinant GHRH discontinued Geref in 2008.[20]

Ipamorelin's randomized trial was in bowel-resection patients, and there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.[4]

Common questions

CJC-1295 ipamorelin vs sermorelin: which is better?

The cited human data are hormone studies: in older men, twice-daily GHRH produced dose-related increases in GH and IGF-I, significant only at the high dose. The cited sources do not compare the options head to head.[8]

Is sermorelin one of the peptides in the blend?

No. The blend is CJC-1295 plus ipamorelin; sermorelin appears in a separate chart review combined with GHRP-6 and GHRP-2.[9]

Is sermorelin still sold as an approved drug?

The review reports that Geref was discontinued by its only US manufacturer in 2008.[20]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  3. 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  4. 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  5. 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  6. 6An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  7. 7Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  8. 8Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  9. 9Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  10. 10Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  11. 11PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  16. 16Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  17. 17Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  18. 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999PMID 18031173Accessed 2 Oct 2026
  20. 20Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026

Found an error? Report a correction.